BofA lowered the firm’s price target on Clorox (CLX) to $125 from $135 and keeps a Neutral rating on the shares. Among the firm’s consumer staples coverage, BofA is “cutting estimates for topline and EPS almost universally” for Q3 with a few exceptions, the analyst tells investors in a preview for the packaged food, beverages, HPC and tobacco groups.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox price target lowered to $128 from $134 at UBS
- Clorox price target lowered to $117 from $120 at TD Cowen
- Clorox price target lowered to $112 from $118 at Barclays
- Clorox’s Financial Challenges and Operational Disruptions Lead to Hold Rating
- Clorox price target raised to $135 from $133 at JPMorgan